Related Experiment Video
Updated: Jun 6, 2025
Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
Published on: March 20, 2020
Identifying therapeutic strategies for triple-negative breast cancer via phosphoproteomics
Yuhan Sheng1,2, Gordon Mills1, Xuejiao Zhao1,3
1Division of Oncological Sciences Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USA.
Introduction:
Given the poor prognosis of patients with TNBC, it is urgent to identify new biomarkers and therapeutic targets to enable personalized treatment strategies and improve patient survival. Comprehensive insights beyond genomic and transcriptomic analysis are crucial to improved outcomes for patients. As proteins are the workhorses of cellular function with their activity primarily regulated by phosphorylation, advanced phosphoproteomics techniques, such as mass spectrometry and antibody arrays, are essential for elucidating kinase signaling pathways that drive TNBC progression and contribute to therapy resistance.
Area Covered:
This review discusses the critical need to integrate phosphoproteomics into TNBC research, evaluates commonly used technologies and their applications, and explores their advantages and limitations. We highlight significant findings from phosphoproteomic analyses in TNBC and address the challenges of implementing these technologies into clinical practice.
Expert Opinion:
Rapid advances in phosphoproteomics analysis facilitate subtype stratification, adaptive response monitoring, and identification of biomarkers and therapeutic targets in TNBC. However, challenges in analyzing protein phosphorylation, especially in deep spatially resolved analysis of malignant cells and the tumor ecosystem, hinder the translation of phosphoproteomics to the CLIA setting. Nonetheless, phosphoproteomics offers a powerful tool that, when integrated into routine clinical practice, has the potential to revolutionize patient care.
Insights
Phosphoproteomics offers new hope for triple-negative breast cancer (TNBC) by revealing therapeutic targets. Integrating these advanced analyses into clinical practice could significantly improve patient outcomes and survival rates.
Area of Science:
- Oncology
- Biochemistry
- Proteomics
Background:
- Triple-negative breast cancer (TNBC) has a poor prognosis, necessitating novel biomarkers and therapeutic targets.
- Genomic and transcriptomic analyses alone are insufficient for comprehensive TNBC patient insights.
- Protein phosphorylation regulates cellular functions and is key to understanding TNBC progression and therapy resistance.
Purpose of the Study:
- To review the critical need for phosphoproteomics in TNBC research.
- To evaluate phosphoproteomics technologies, their applications, advantages, and limitations.
- To highlight key findings and discuss implementation challenges in clinical practice.
Main Methods:
- Review of current literature on phosphoproteomics techniques (e.g., mass spectrometry, antibody arrays).
- Analysis of phosphoproteomic data applications in TNBC subtype stratification and biomarker discovery.
- Discussion of challenges in spatial resolution and clinical translation.
Main Results:
- Phosphoproteomics advances enable subtype stratification and adaptive response monitoring in TNBC.
- Identification of potential biomarkers and therapeutic targets through phosphoproteomic analysis.
- Significant findings from phosphoproteomic studies in TNBC are highlighted.
Conclusions:
- Phosphoproteomics is a powerful tool for advancing TNBC research and patient care.
- Challenges remain in clinical translation, particularly in detailed spatial analysis.
- Integration into routine clinical practice holds potential to revolutionize TNBC patient management.
More Related Videos
12:23Phosphopeptide Enrichment Coupled with Label-free Quantitative Mass Spectrometry to Investigate the Phosphoproteome in Prostate Cancer
Published on: August 2, 2018
07:42Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays
Published on: September 19, 2018
